Last reviewed · How we verify

Oral Pyridoxine 10 mg

National University of Malaysia · FDA-approved active Small molecule Quality 5/100

Oral Pyridoxine 10 mg is a Small molecule drug developed by National University of Malaysia. It is currently FDA-approved. Also known as: MSA Pyridoxine HCI 10 mg Tablet.

Oral Pyridoxine 10 mg, developed by the National University of Malaysia, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and patent protection, which provides a competitive barrier until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameOral Pyridoxine 10 mg
Also known asMSA Pyridoxine HCI 10 mg Tablet
SponsorNational University of Malaysia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral Pyridoxine 10 mg

What is Oral Pyridoxine 10 mg?

Oral Pyridoxine 10 mg is a Small molecule drug developed by National University of Malaysia.

Who makes Oral Pyridoxine 10 mg?

Oral Pyridoxine 10 mg is developed and marketed by National University of Malaysia (see full National University of Malaysia pipeline at /company/national-university-of-malaysia).

Is Oral Pyridoxine 10 mg also known as anything else?

Oral Pyridoxine 10 mg is also known as MSA Pyridoxine HCI 10 mg Tablet.

What development phase is Oral Pyridoxine 10 mg in?

Oral Pyridoxine 10 mg is FDA-approved (marketed).

Related